April 6, 2023

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked
reputable news agency
proofread

Model developed for predicting disease progression in hep B liver cirrhosis

× close

For patients with hepatitis B virus (HBV) liver cirrhosis-acute decompensation (LC-AD), a model combining computed tomography (CT) quantified extracellular liver volume (ECVIC-liver) and chronic liver failure consortium-acute decompensation score (CLIF-C ADs) can predict the occurrence of acute-on-chronic liver failure (ACLF), according to a study published online March 29 in Insights into Imaging.

Yang Xu, from Lanzhou University Second Hospital in China, and colleagues conducted a to develop and validate a for predicting the occurrence of ACLF within 90 days in with HBV LC-AD. Participants underwent dual-energy CT scans of the liver and were randomly assigned to a training group and a validation group (215 and 92 patients, respectively). The need for readmission within 90 days due to ACLF was the primary outcome.

The researchers found that CLIF-C ADs and ECVIC-liver were independent risk factors for ACLF. In the training and validation groups, the area under the receiver operating characteristic curves of the model combining CLIF-C ADs and ECVIC-liver were 0.893 and 0.838, respectively. Good agreement was seen between predicted and actual risks in calibration curves. The model had good clinical application in a decision curve analysis.

"The results of this study can be used to assist the clinic to better identify the early disease progression in LC-AD patients," the authors write.

More information: Yuan Xu et al, Dual-energy CT quantification of extracellular liver volume predicts short-term disease progression in patients with hepatitis B liver cirrhosis-acute decompensation, Insights into Imaging (2023). DOI: 10.1186/s13244-023-01393-x

Load comments (0)